Cwm LLC cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 17.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 625 shares of the medical research company’s stock after selling 134 shares during the quarter. Cwm LLC’s holdings in Bio-Rad Laboratories were worth $209,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Fulton Bank N.A. bought a new stake in Bio-Rad Laboratories during the third quarter valued at $224,000. RK Asset Management LLC bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $5,198,000. GAMMA Investing LLC grew its stake in Bio-Rad Laboratories by 66.7% during the third quarter. GAMMA Investing LLC now owns 535 shares of the medical research company’s stock worth $179,000 after purchasing an additional 214 shares during the period. Handelsbanken Fonder AB increased its holdings in Bio-Rad Laboratories by 20.6% in the third quarter. Handelsbanken Fonder AB now owns 5,272 shares of the medical research company’s stock worth $1,764,000 after purchasing an additional 900 shares in the last quarter. Finally, Paragon Capital Management Inc. acquired a new position in Bio-Rad Laboratories in the second quarter valued at approximately $1,309,000. Institutional investors own 65.24% of the company’s stock.
Insider Activity at Bio-Rad Laboratories
In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Research Report on BIO
Bio-Rad Laboratories Trading Down 0.9 %
Shares of BIO opened at $340.10 on Wednesday. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $364.24. The stock has a market cap of $9.70 billion, a PE ratio of -32.83 and a beta of 0.95. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $330.87 and its 200-day moving average price is $307.14.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. During the same period in the prior year, the business earned $3.00 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was down 6.3% compared to the same quarter last year. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Articles
- Five stocks we like better than Bio-Rad Laboratories
- Top Biotech Stocks: Exploring Innovation Opportunities
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What Are the FAANG Stocks and Are They Good Investments?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Best Aerospace Stocks Investing
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.